Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 10.73
- Piotroski Score 1.00
- Grade Neutral
- Symbol (EPIX)
- Company ESSA Pharma Inc.
- Price $1.85
- Changes Percentage (4.52%)
- Change $0.08
- Day Low $1.76
- Day High $1.85
- Year High $11.67
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 12/09/2024
- Fiscal Year End N/A
- Average Stock Price Target $9.50
- High Stock Price Target $17.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.63
- Trailing P/E Ratio -9.08
- Forward P/E Ratio -9.08
- P/E Growth -9.08
- Net Income $-26,582,343
Income Statement
Quarterly
Annual
Latest News of EPIX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
ESSA Pharma Inc. (EPIX): Wall Street Analysts Recommend This Canadian Stock Right Now
ESSA Pharma Inc. is one of the top Canadian stocks to buy, focusing on prostate cancer therapies. The company's lead drug candidate shows promising results in clinical trials. Financially strong, ESSA...
By Yahoo! Finance | 1 month ago -
With 40% stake, ESSA Pharma Inc. (NASDAQ:EPIX) seems to have captured hedge funds investors' interest
Ownership data, like hedge fund shares in ESSA Pharma, reveals powerful stakeholders. Institutional investors' stakes also indicate credibility, but reliance on them can be risky. Analyst forecasts, a...
By Yahoo! Finance | 4 months ago
